On Average 3.5 patents per drug in 2005! and How private-sector follow-on patents affect socially responsible licensing efforts.

(…) This Note proceeds in four Parts.

Part I examines the role of patents in drug development and the regulatory environment under the Hatch-Waxman Act.

Part II discusses ways in which follow-on patents can impede socially responsible licensing efforts by universities and other public-sector institutions.

Part III presents an empirical analysis of drug patent data, which shows that the number of patents per drug has increased over time, and examines factors that have influenced this trend. (…)

Part IV describes a table of detailed patent information for eighteen recently approved drugs with both public- and private-sector patents and discusses the implications of these results for university patenting and licensing. (…)

 

HOW MANY PATENTS DOES IT TAKE TO MAKE A DRUG? FOLLOW-ON
PHARMACEUTICAL PATENTS AND
UNIVERSITY LICENSING

Lisa Larrimore Ouellette

http://www.mttlr.org/volseventeen/ouellette.pdf

17 Michigan Telecommunications and Technology Law Review 299 (2010)

 

Advertisements

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s